✦ LIBER ✦

Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433

✍ Scribed by Komaki, Ritsuko; Pajak, Thomas F.; Byhardt, Roger W.; Emami, Bahman; Asbell, Sucha O.; Roach, Mack; Pedersen, John E.; Curran, Walter J.; Lattin, Paul; Russell, Anthony H.; Cox, James D.

Book ID: 122967082
Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 622 KB
Volume: 10
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(93)90179-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analysis of early and lats deaths on RTO

Analysis of early and lats deaths on RTOG non-small cell lung carcinoma trials vs. CALGB 8433

✍ R. Komahi; T.F. Pajak; R.W. Byhardt; I. Emami; S.O. Asbell; M. Roach; J.E. Peder 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Acute Esophagitis and Late Lung Toxicity

Acute Esophagitis and Late Lung Toxicity in Concurrent Chemoradiotherapy Trials in Patients with Locally Advanced Non–Small-Cell Lung Cancer: Analysis of the Radiation Therapy Oncology Group (RTOG) Database

✍ Maria Werner-Wasik; Rebecca Paulus; Walter J. Curran Jr.; Roger Byhardt 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 330 KB

Trial on Refinement of Early stage non-s

Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol

✍ Michael Kreuter; Johan Vansteenkiste; Frank Griesinger; Hans Hoffmann; Hendrik D 📂 Article 📅 2007 🏛 BioMed Central 🌐 English ⚖ 312 KB

Does clinical experience with a treatmen

Does clinical experience with a treatment regimen affect survival of lung cancer patients? An analysis based on consecutive randomized trials of the Medical Research Council in small cell and non-small cell tumours

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 57 KB

O7 An exploratory analysis of the impact

O7 An exploratory analysis of the impact of age, performance status, and comorbidity on clinical outcomes in a randomized phase II trial of single agent gemcitabine, vinorelbine or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly

✍ Ngeow, J.; Poon, D.; Leong, S.S.; Gao, F.; Toh, C.K.; Lim, W.T.; Xu, L.; Tan, S. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 58 KB